1Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971, 285(21): 1182.
2O'Reilly M S, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth [ J ]. Cell, 1997, 88(2): 277.
3Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance[J]. Nature, 1997, 390(6658): 404.
4Marshall E. Cancer therapy. Setbacks for endostatin[J]. Science, 2002, 295(5563): 2198.
5Tjin Tham Sjin R M, Satchi-Fainaro R, Birsner AE, et al. A 27-amino-acid synthetic peptide corresponding to the NH2 -terminal zinc-binding domain of endostatin is responsible for its antitumor activity[J]. Cancer Res, 2005, 65(9) : 3656.
6Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors[J]. Clin Cancer Res, 2003, 9(1 ) : 377.
7Huang X, Wong M K, Zhao Q, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect [ J]. Cancer Res, 2001, 61 (2) : 478.
8Yokoyama Y, Green J E, Sukhatme V P, et al. Effect of Endostatin on Spontaneous Tumorigenesis of Mammary Adenocarcinomas in a Transgenic Mouse Model[J ]. Cancer Res, 2000, 60(16): 4362.
9Plum S M, Hanson A D Volker K M, el al. Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model [J]. Clin Cancer Res, 2003, 9(12): 4619.
10Beck M T, Chen N Y, Franek K J, et al. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer[J]. Cancer Res, 2003, 63(13): 3598.
4Gebbia V,Galetta D, Riccardi F, et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage Ⅲ B- Ⅳ non-small cell lung carcinoma: a prospective randomized study[J]. Lung Cancer ,2002,37(2): 179 - 187.
5Fossella F, Pereira JR, yon Pawel J, et al. Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group [ J ]. J Clin Oncol, 2003,21 (16) :3016 - 3024.
6Chen YM,Lee CS, Lin WC. Phase Ⅱ study with vinorelbine and cisplatin in advanced non-small cell lung cancer after failure of previous chemotherapy [ J ]. J Chin Med Assoc, 66 ( 4 ): 241 - 246.
7Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[ J ]. N Engl J Med , 2004,350 (23): 2335 - 2342.
8Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: Endogenous inhibitors of tumour growth[J]. Cancer Metastasis Rev, 2000,19 ( 1 - 2): 181 - 190.
9Yoon SS, Eto H, Lin CM, et al. Mouse endostatin inhibits the formation of lung and liver metastases[J]. Cancer Res, 1999,59(24) :6251 - 6256.
10Yokoyama Y, Dhanabal M, Griffioen AW, et al. Synergy be tween angiostatin and endostatin: Inhibition of ovarian cancer growth[J]. Cancer Res ,2000,60(8) :2190 - 2196.
